Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

BACKGROUND: Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%–90% of these cancers. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Norum, Jan, Nieder, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173248/
https://www.ncbi.nlm.nih.gov/pubmed/30305940
http://dx.doi.org/10.1136/esmoopen-2018-000406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173248/
https://www.ncbi.nlm.nih.gov/pubmed/30305940
http://dx.doi.org/10.1136/esmoopen-2018-000406

Ejemplares similares